Key result
Doxorubicin and 5-FU reveal 912 cardiac response eGenes, with ~36% shared across treatments.
Why the study?
Doxorubicin and 5-fluorouracil frequently cause severe adverse cardiovascular events that force chemotherapy interruptions, and the specific genetic loci mediating cell-type-specific cardiac and vascular responses to these agents remained to be identified.
Does acute in vitro exposure to doxorubicin or 5-fluorouracil alter cell-type-specific gene expression and reveal genetic regulatory variants (response eQTLs) associated with cardiotoxicity across human iPSC-derived cardiac cell types?
Does acute in vitro exposure to doxorubicin or 5-fluorouracil alter cell-type-specific gene expression and reveal genetic regulatory variants (response eQTLs) associated with cardiotoxicity across human iPSC-derived cardiac cell types?
Answers are grounded in this paper and cite their sources.
This single-cell eQTL study in human iPSC-derived cardiac cultures identifies hundreds of cell-type-specific genetic variants that modify transcriptional responses to doxorubicin and 5-fluorouracil, supporting the development of genotype-based predictors for chemotherapy-induced cardiotoxicity.
Doxorubicin ( DOX ) and 5-fluorouracil ( 5-FU ) are effective for treating a variety of cancers, yet many patients taking these drugs experience adverse cardiovascular events that are severe enough to pause treatment, often prolonging the course of chemotherapy and reducing its efficacy. Individual risk for drug-induced cardiotoxicity is likely mediated, at least in part, by genetic variants that control how the heart and vasculature respond to drug-induced perturbations. To identify loci associated with drug-induced cardiotoxicity, we developed an in vitro model that allows us to characterize the effects of chemotherapeutic drugs on a wide range of cardiac cell types, including cardiomyocytes, endothelial cells, and fibroblasts. Using single-cell RNA-seq, we profiled responses to DOX and 5-FU across 46 individuals and 14 cell types, identifying hundreds of expression quantitative trait loci that modify cardiovascular transcription in response to each drug ( response eQTLs ). Drug-responsive eQTL genes include genes that were previously linked to drug-induced cardiotoxicity and cardiovascular disease, such as ABCB4 , HAS3 , TNFRSF1A , and OGFR . Over a third of drug-responsive genes are shared between the DOX and 5-FU treatments, suggesting that genes predictive of DOX-induced cardiotoxicity may extend to 5-FU. Among the credible colocalizations we identified between GWAS signals and drug-response eQTLs, we discovered a locus associated with ischemic heart disease that is also a DOX-responsive eQTL for IL6R. IL6R was previously nominated as a druggable target for heart disease, and its binding partner IL6 is a candidate biomarker for anthracycline-induced cardiotoxicity. These findings advance the discovery of genetic variants underlying cardiotoxicity and support development of genotype-based predictors for treating cancer.
No takes yet. Share an insight, caveat, or question.
McIntire et al. (2026) studied Drug-induced cardiotoxicity (n=46). Doxorubicin (DOX) and 5-fluorouracil (5-FU) vs. Vehicle control (dimethyl sulfoxide, DMSO) was evaluated on Drug-responsive expression quantitative trait loci (response eQTLs) and associated eGenes across cardiovascular cell types. Doxorubicin and 5-fluorouracil exposure across 46 iPSC-derived cardiac cultures identified 912 drug-response eGenes (665 for DOX, 573 for 5-FU), with 35.7% shared between treatments.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: